Nephropathy in diabetes

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 107-122

  Satirapoj, Bancha ^a  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALDOSTERONE ANTAGONIST; AMINOGUANIDINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; PLACEBO; POLYOL; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; SPIRONOLACTONE; SULODEXIDE; TELMISARTAN; VASOPEPTIDASE INHIBITOR;

ALBUMINURIA; ARTICLE; BEHAVIOR MODIFICATION; BLOOD PRESSURE REGULATION; CELL EXPANSION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DYSLIPIDEMIA; END STAGE RENAL DISEASE; ENZYME ACTIVATION; EXERCISE; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MESANGIUM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN GLYCOSYLATION; PROTEIN RESTRICTION; PROTEINURIA; RENAL PROTECTION; RISK FACTOR; SMOKING CESSATION; SODIUM RESTRICTION; URINALYSIS; WEIGHT REDUCTION; KIDNEY; PHYSIOLOGY; REVIEW;

DIABETIC NEPHROPATHIES; HEMODYNAMICS; HUMANS; HYPERGLYCEMIA; KIDNEY; OXIDATIVE STRESS; RISK FACTORS;

MLCS; MLOWN;

EID: 84874533863     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5441-0_11     Document Type: Article

References (81)

1. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27:167-194.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care 1998; 21:1414-1431.
3. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341:1127-1133.
4. Ngarmukos C, Bunnag P, Kosachunhanun N et al. Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy. J Med Assoc Thai 2006; 89 Suppl 1:S37-S42.
5. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225-232.
6. Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. American Diabetes Association and the National Kidney Foundation. Diabetes Care 1994; 17:1357-1361.
7. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49:S12-S154.
8. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983; 32 Suppl 2:64-78.
9. Bank N. Mechanisms of diabetic hyperfiltration. Kidney Int 1991; 40:792-807.
10. Parving HH. Renoprotection in diabetes: genetic and nongenetic risk factors and treatment. Diabetologia 1998;41:745-759.
11. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 2006; 49:11-19.
12. Satirapoj B, Supasyndh O, Dispan R et al. Insulin resistance and type 2 diabetes patients in difference stage of nephropathy. Royal Thai Army Medical Journal 2009; 62:113-122.
13. Seaquist ER, Goetz FC, Rich S et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320:1161-1165.
14. Quinn M, Angelico MC, Warram JH et al. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996; 39:940-945.
15. Trevisan R, Viberti G. Genetic factors in the development of diabetic nephropathy. J Lab Clin Med 1995; 126:342-349.
16. Iyengar SK, Abboud HE, Goddard KA et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). Diabetes 2007; 56:1577-1585.
17. Adler S, Pahl M, Abboud H et al. Mexican-American admixture mapping analyses for diabetic nephropathy in type 2 diabetes mellitus. Semin Nephrol 2010; 30:141-149.
18. Satirapoj B. Diabetic kidney disease: important mechanisms and treatment. J Nephrol Soc Thai 2009; 15:126-139.
19. Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease. J Med Assoc Thai 2010; 93 Suppl 6:S228-S241.
20. Nagai Y, Yao L, Kobori H et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16:703-711.
21. Sharma K, Eltayeb BO, McGowan TA et al. Captopril-induced reduction of serum levels of transforming growth factor-betal correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999; 34:818-823.
22. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008; 4:39-45.
23. Mishra R, Emancipator SN, Kern T et al. High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. Kidney Int 2005; 67:82-93.
24. Heilig CW, Concepcion LA, Riser BL et al. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 1995; 96:1802-1814.
25. Dai T, Natarajan R, Nast CC et al. Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton. Kidney International 2006; 69:806-814.
26. Singh AK, Mo W, Dunea G et al. Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol 1998; 9:802-810.
27. Haneda M, Kikkawa R, Sugimoto T et al. Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. J Diabetes Complications 1995; 9:246-248.
28. Menne J, Meier M, Park JK et al. Inhibition of protein kinase C in diabetic nephropathy-where do we stand? Nephrol Dial Transplant 2009; 24:2021-2023.
29. Tilton RG, Chang K, Pugliese G et al. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 1989; 38:1258-1270.
30. Ha H, Hwang IA, Park JH et al. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 2008; 82 Suppl 1:S42-S45.
31. Dandona P, Thusu K, Cook S et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996;347:444-445.
32. Brezniceanu ML, Liu F, Wei CC et al. Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int 2007; 71:912-923.
33. Lee HB, Yu MR, Yang Y et al. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003; 14:S241-S245.
34. Suzuki D, Miyata T, Saotome N et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999; 10:822-832.
35. Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int 1994; 45:612-622.
36. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99:342-348.
37. Tervaert TW, Mooyaart AL, Amann K et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010;21:556-563.
38. Parving HH, Hommel E, Mathiesen E et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988; 296:156-160.
39. Parving HH, Gall MA, Skott P et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41:758-762.
40. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-986.
41. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-853.
42. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
43. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
44. Kawazu S, Tomono S, Shimizu M et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study. J Diabetes Complications 1994; 8:13-17.
45. Mulec H, Blohme G, Grande B et al. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant 1998; 13:651-655.
46. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
47. Fioretto P, Steffes MW, Sutherland DE et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339:69-75.
48. Fioretto P, Sutherland DE, Najafian B et al. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006; 69:907-912.
49. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203.
50. Zatz R, Dunn BR, Meyer TW et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77:1925-1930.
51. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
52. Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271:275-279.
53. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 1996; 39:587-593.
54. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
55. Wilmer WA, Hebert LA, Lewis EJ et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999; 34:308-314.
56. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
57. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
58. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951.
59. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-1961.
60. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321:1440-1444.
61. Jacobsen P, Andersen S, Rossing K et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63:1874-1880.
62. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-553.
63. Kramer AB, van der Meulen EF, Hamming I et al. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 2007; 71:417-424.
64. Rossing K, Schjoedt KJ, Smidt UM et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28:2106-2112.
65. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68:2829-2836.
66. van den Meiracker AH, Baggen RG, Pauli S et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24:2285-2292.
67. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46:45-51.
68. Agarwal R. Effects of statins on renal function. Mayo Clin Proc 2007; 82:1381-1390.
69. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145:117-124.
70. Zeller K, Whittaker E, Sullivan L et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324:78-84.
71. Walker JD, Bending JJ, Dodds RA et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 1989; 2:1411-1415.
72. Hansen HP, Tauber-Lassen E, Jensen BR et al. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002; 62:220-228.
73. Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19:999-1007.
74. Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 1996; 125:201-204.
75. Houlihan CA, Allen TJ, Baxter AL et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002; 25:663-671.
76. Esnault VL, Ekhlas A, Delcroix C et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16:474-481.
77. de Boer IH, Sibley SD, Kestenbaum B et al. Central obesity, incident microalbuminuria and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 2007; 18:235-243.
78. Morales E, Valero MA, Leon M et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319-327.
79. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.
80. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393.
81. Goh SY, Jasik M, Cooper ME. Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs 2008; 13:447-463.